| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657556 | Clinical Gastroenterology and Hepatology | 2017 | 41 Pages |
Abstract
In a systematic review, we found treatment of HCV genotype 1 infection with second-generation DAAs to be cost-effective when they cost less than and $227,200; these drugs produced cost savings at current discounts.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jagpreet Chhatwal, Tianhua He, Chin Hur, Maria A. Lopez-Olivo,